6ÔÂ5ÈÕ£¬ng28ÄϹ¬Öêʽ»áÉ磨×ܲ¿Î»ÓÚÈÕ±¾¶«¾©£¬ÏÖÈÎÉ糤ΪÄÚÌÙÇç·ò£¬ÒÔϼò³Æ”ng28ÄϹ¬”£©Ðû²¼£¬ÔÚÃÀ¹úÖ¥¼Ó¸ç¾ÙÐеÄÃÀ¹úÁÙ´²Ö×Áöѧ»á£¨ASCO£©µÚ53½ìÄê»áÉÏÐû²¼ÁËÆä×ÔÖ÷Ñз¢µÄ¶à¼¤Ã¸ÒÖÖƼÁ?¡ª?¼×»ÇËáÀÖ·¥ÌæÄᣨlenvatinib mesylate£©£¨ÉÌÆ·Ãû£ºLenvima? / Kisplyx?£¬”ÀÖ·¥ÌæÄᔣ©ÁªºÏĬɳ¶«£¨MSD£¬Î»ÓÚÃÀ¹úÐÂÔóÎ÷ÖÝ¿ÏÄɶûÎÖ˹±¤£¬ÔÚÃÀ¹úºÍ¼ÓÄôó³ÆΪĬ¿Ë£¨Merck£©£©¿ª·¢µÄanti-PD-1¿¹ÌåÅÁÄ·µ¥¿¹£¨pembrolizumab£©£¨ÉÌÆ·Ãû£ºKEYTRUDA?*£©ÓÃÓÚÖÎÁÆתÒÆÐÔ×Ó¹¬ÄÚĤ°©µÄµÚIb/IIÆڵĿª¶ËÑо¿½á¹û¡£Á½¼Ò¹«Ë¾ÕýÔÚÏàÖú̽Ë÷ÕâÒ»ÁªºÏÁÆ·¨¡£ÆäÕýÔÚ½øÐеÄ111Ñо¿½«ÆÀ¹ÀÀÖ·¥ÌæÄá/ÅÁÄ·µ¥¿¹Õâ¶ÔÒ©Îï×éºÏ¶ÔÏà¹ØʵÌåÁöµÄÖÎÁÆ×÷Óá£
¶Ô23λ×Ó¹¬ÄÚĤ°©»¼ÕßÔÚ¸ÃÑо¿µÄIB/ IIÆÚµÄÁÆЧÆÊÎö½á¹û½øÐÐÁ˱¨µÀ¡£ÕâЩ»¼Õß¼ÈÍùÖÁÉÙ½ÓÊܹýÒ»¸ö»¯ÁƼƻ®¡£ÔÚ½ÓÊÜÀÖ·¥ÌæÄáºÍÅÁÄ·µ¥¿¹ÁªºÏÖÎÁƺó£¬ÆÊÎö½á¹û±êÃ÷£¬ÆäÖ÷ÒªÖյ㣬¾¶ÀÁ¢Ó°ÏñѧÆÀ¹À£¨IRR£©µÄ¿Í¹Û·´Ó¦ÂÊΪ52.2%£¨95%ÖÃÐÅÇø¼ä[CI] = 30.6¨C73.2£©£¬¾Ñо¿ÕßÆÀ¹ÀµÄ¿Í¹Û·´Ó¦ÂÊΪ47.8%£¨95%ÖÃÐÅÇø¼ä[CI] = 26.8¨C69.4£©¡£
´ÎÒªÖÕµãÖо¶ÀÁ¢Ó°ÏñѧÆÀ¹À£¨IRR£©µÄÁÙ´²»ñÒæÂÊ**Ϊ65.2%£¨95% CI£º42.7 – 83.6£©£¬¾Ñо¿ÕßÆÀ¹ÀµÄÁÙ´²»ñÒæÂÊΪ73.9%£¨95% CI£º51.6 – 89.8£©¡£¾¶ÀÁ¢·ÅÉäÐÔÆÀ¹À£¨IRR£©µÄ¼²²¡¿ØÖÆÂÊ***Ϊ91.3%£¨95% CI£º72.0 – 98.9£©£¬¾Ñо¿ÕßÆÀ¹ÀµÄ¼²²¡¿ØÖÆÂÊΪ95.7%£¨95% CI£º78.1 – 99.9£©¡£¾Ñо¿ÕßÆÀ¹ÀµÄÖÐλÎÞ½øÕ¹Éú´æÆÚΪ9.7¸öÔ£¨95% CI£º4.2 – NE£©£¬Î´»ñµÃ¾¶ÀÁ¢Ó°ÏñѧÆÀ¹À£¨IRR£©µÄÖÐλÎÞ½øÕ¹Éú´æÆÚµÄÊý¾Ý¡£ÌìÖ°Îö½ÚµãÒàδ»ñµÃÖÐλ·´Ó¦Á¬Ðøʱ¼äµÄÊý¾Ý¡£
Anti-PD-1¿¹ÌåÒ»°ã¶Ô»¼ÓиßƵÂʵÄ΢ÎÀÐDz»Îȶ¨ÐÔ£¨MSI£©µÄ»¼Õ߸üΪÓÐЧ£¬ÕâÖÖÉúÎï±ê¼ÇÎï»áµ¼ÖÂDNA´íÅäÐÞ¸´¹¦Ð§ÕÏ°£¬¶ø¶ÔÆäËû²¡ÈËÔò²»ÄÇôÓÐЧ¡£È»¶ø£¬ÔÚ±¾´ÎÑо¿ÖУ¬ÎÞÂÛ²¡È˵Ä΢ÎÀÐDz»Îȶ¨ÐÔ£¨MSI£©×´Ì¬ÈçºÎ£¬ÁªºÏÖÎÁƶ¼ÊӲ쵽Ö×Áö»º½â£¬ÆäÖ×Áö״̬ÓÐËùºÃת¡£
¸ÃÁªºÏÁÆ·¨µÄ×î³£¼ûµÄÎåÖÖ²»Á¼·´Ó¦Îª£»¸ßѪѹ£¬Æ£ÀÍ£¬ÊàŦʹ£¬¸¹Ðº£¬¶ñÐÄ¡£
×Ó¹¬ÄÚĤ°©ÊÇÈ«ÇòÅ®ÐÔÖеĵÚÁù´ó³£¼û¶ñÐÔÖ×Áö£¬2012ÄêÓÐ320000ÀýÐÂÈ·ÕﲡÀý£¬¾ÝÔ¤¼Æ£¬2017ÄêÔÚÃÀ¹úԼĪ»áÓÐ60000ÃûÅ®ÐÔ±»ÐÂÕï¶ÏΪ×Ó¹¬ÄÚĤ°©£¬Ô¼10000ÃûÅ®ÐÔËÀÓڸò¡¡£Òò´ËÔڸü²²¡ÁìÓòÈÔ±£´æ×ÅÖØÒª¶øδÂú×ãµÄÒ½ÁÆÐèÇó£¬ÓÐÐëÒª¿ª·¢ÐµÄÖÎÁÆÒªÁì¡£
ng28ÄϹ¬½«Ö×ÁöÊÓΪ¹«Ë¾µÄÒ»¸öÒªº¦ÖÎÁÆÁìÓò£¬ÖÂÁ¦ÓÚÑз¢ÓпÉÄÜÖÎÓú°©Ö¢µÄ¸ïÃüÐÔÐÂÒ©Îï¡£ng28ÄϹ¬½«¼ÌÐø̽Ë÷¿Æѧ֤¾Ý£¬Ê¹ÀÖ·¥ÌæÄáÄܹ»ÔÚδÀ´×î´óÏ޶ȵØÂú×㻼Õ߶àÑù»¯µÄÐèÇ󣬲¢Îª°©Ö¢»¼Õß¡¢»¼Õß¼ÒÊô¼°Ò½ÁÆ´ÓÒÃ÷ÈÕß´øÀ´¸ü¶à¸£ìí¡£
*???? Keytruda?ÊÇĬɳ¶«¹«Ë¾£¨Merck Sharp & Dohme Corp£©µÄÒ»¸ö×¢²áÉ̱ꡣĬɳ¶«¹«Ë¾ÊÇλÓÚÃÀ¹úÐÂÔóÎ÷ÖÝ¿ÏÄɶûÎÖ˼±¤µÄĬ¿ËÓÐÏÞ¹«Ë¾£¨Merck & Co.£¬Inc£©µÄÒ»¸ö×Ó¹«Ë¾¡£ **?? ÁÙ´²ÊÜÒæÂÊ£ºÍêÈ«»º½â+²¿·Ö»º½â+ά³Ö¼²²¡Îȶ¨µÖ´ï23ÖÜ»ò¸ü³¤Ê±¼äµÄ»¼Õ߰ٷֱȡ£ *** ¼²²¡¿ØÖÆÂÊ£ºÍêÈ«»º½â+²¿·Ö»º½â+ά³Ö¼²²¡Îȶ¨µÖ´ï5ÖÜ»ò¸ü³¤Ê±¼äµÄ»¼Õ߰ٷֱȡ£